Search results
Results from the WOW.Com Content Network
Titan's principal asset is Probuphine, [5] [6] a slow-release implant formulation of buprenorphine [7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. [8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. [6]
Endo is one of the companies named in lawsuits by the states of Ohio, [42] Missouri and Mississippi [43] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. [44]
Chattem, Inc. is an American, Chattanooga, Tennessee-based, producer and marketer of over-the-counter healthcare products, toiletries, dietary supplements, topical analgesics, and medicated skin care products.
McKinsey & Company agreed to pay $650 million to resolve criminal and civil investigations into its advice to opioids manufacturer Purdue Pharma. ... at Le Bourget Airport near Paris, France, June ...
A US Drug Enforcement Administration (DEA) database tracking every opioid pill sold in the United States from 2006 through 2012 was made public in 2019. The database "attributed the vast majority of the 76 billion opioid pills produced and shipped from 2006 through 2012 to three companies", one of which was SpecGx, a subsidiary of Mallinckrodt.
The law (TN Code 53-11-311) that prevents nurse practitioners (NPs) or physician assistants (PAs) from prescribing more than 16 milligrams of buprenorphine-naloxone daily (despite standard dosing ...
BOSTON (Reuters) -McKinsey & Co has agreed to pay $650 million to resolve a U.S. Department of Justice investigation into the consulting firm's work advising opioid manufacturer OxyContin maker ...
This is the list of Schedule II controlled substances in the United States as defined by the ... opiate Codeine [2] 9334 opiate Dihydroetorphine [3] 9190 opiate ...